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Abstract
Aurora kinase inhibitors are new mitosis-targeting drugs currently in clinical trials for the treatment of haematological and
solid malignancies. However, knowledge of the molecular factors that influence sensitivity and resistance remains limited.
Herein,wedevelopedand characterisedan invitroleukaemiamodel of resistanceto theAuroraB inhibitorZM447439.Human
T-cell acute lymphoblastic leukaemia cells, CCRF-CEM, were selected for resistance in 4 mM ZM447439. CEM/AKB4 cells
showed no cross-resistance to tubulin-targeted and DNA-damaging agents, but were hypersensitive to an Aurora kinase A
inhibitor. Sequencing revealed a mutation in the Aurora B kinase domain corresponding to a G160E amino acid substitution.
Molecular modelling of drug binding in Aurora B containing this mutation suggested that resistance is mediated by the
glutamate substitution preventing formation of an active drug-binding motif. Progression of resistance in the more highly
selected CEM/AKB8 and CEM/AKB16 cells, derived sequentially from CEM/AKB4 in 8 and 16 mM ZM447439 respectively, was
mediated by additional defects. These defects were independent of Aurora B and multi-drug resistance pathways and are
associated with reduced apoptosis mostly likely due to reduced inhibition of the catalytic activity of aurora kinase B in the
presence of drug. Our findings are important in the context of the use of these new targeted agents in treatment regimes
against leukaemia and suggest resistance to therapy may arise through multiple independent mechanisms.
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Introduction
Mitotic kinases play crucial roles in regulation of cell division, yet
aberrations in their expression and function are known to be
involved in cancer initiation and progression. Targeting these
kinases has proven in recent years to be an exciting avenue for
alternative cancer therapies [1]. The Aurora kinases have emerged
as particularly promising targets due their roles in regulating
multiple signalling pathways crucial for accurate cell division.
Localization and function of each subtype – Aurora A, B and C, has
been studied and reviewed extensively in the recent literature [2,3].
The association and implication of the Aurora kinases in cancer
stems from early studies that revealed aberrant expression of both
Aurora A and B in many solid and hematological malignancies.
This association of Aurora kinase overexpression with a malignant
phenotype has been functionally validated [4,5,6,7,8]. Deregulation
of the Aurora kinases disrupts mitotic processes crucial for accurate
cell division leading to chromosomal instability and aneuploidy
[9,10] however a complete understanding of their role in
tumourigenesis remains elusive. Reports of the role and function
of Aurora A and B in leukaemia have been largely limited to
expression studies in cell lines and small cohort clinical studies.
Increased expression of Aurora A has been reported in many
leukaemias, while the expression of Aurora B has shown no clear
trend [11,12,13]. Despite this, both Aurora A and B have been
exploited as potential targets for therapeutic intervention.
The promise of the Aurora kinases as anticancer targets has
been such that small molecule inhibition as drug therapy is a
rapidly developing area of research [2,14]. Early successful
candidates in preclinical testing were pan-Aurora inhibitors such
as VX-680 [15], however it was shown that the dominant
phenotype arising from these agents was that of Aurora B
inhibition [16]. Aurora B specific inhibitors such as AZD1152 [17]
have since shown increasing promise and have reached early stage
clinical trials against both solid and haematological malignancies.
The earliest documented Aurora B inhibitor ZM447439 has also
been well characterised as a probe of the cellular biology of Aurora
B [18]. Cellular phenotypes of these agents such as inhibition of
histone H3 phosphorylation, cytokinesis failure, and polyploidisa-
tion are consistent with inhibition of Aurora B.
As yet, however, the specific factors that will influence sensitivity
and resistance to Aurora kinase inhibitors have not been
adequately addressed. A major drawback of molecularly targeted
agents is the likelihood of acquired clinical resistance. Early success
of the BCR-ABL kinase targeting drug Imatinib in the treatment
of chronic myelogenous leukaemia was followed by the rapid
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mediated by point mutations in the kinase domain preventing drug
binding but maintaining catalytic activity [19]. Identification of
these resistance conferring mutations has led to the design of later-
generation inhibitors that circumvent these changes and allowed
successful treatment of Imatinib resistant patients [20]. Experience
with other agents targeting a single kinase, such as for inhibitors
of EGFR, FLT3, KIT and PDGFR kinases, shows resistance
mediated by kinase domain mutations is a recurring theme.
It appears that resistance mediated by kinase domain mutations is
also a distinct possibility for Aurora kinase inhibitors. A recent in
vitro study reported four point mutations in colorectal cell lines
selected for resistance to ZM447439,with functional studies showing
that each mutation independently conferred a resistant phenotype
[21]. These reported mutations in a colorectal cancer cell line may
be just a subset of possible changes and it is not clear whether other
point mutations would appear in other tumour types. Moreover,
while clinical resistance can clearly be mediated through kinase
mutations, the emergence of other novel resistance pathways in a
clinical setting may be possible. Engagement of alternative survival
pathways and the recently described ‘‘retreatment response’’ [22]
upon multiple drug exposures are examples of non-mutational
mechanisms in targeted drug resistance. The interplay of these
independent resistance pathways and their relative contribution to a
resistant phenotype is still unclear for most anticancer agents,
particularly ina clinical context. An understanding of these networks
is crucial in designing optimal treatment approaches for targeted
therapies, such as Aurora B inhibitors.
In this study we report the development of a leukaemia
resistance model and the characterisation of resistance mecha-
nisms associated with the Aurora B inhibitor ZM447439. We also
investigated the evolution of the resistance phenotype and show
that multiple mechanisms of resistance emerge with increasing
drug resistance levels.
Materials and Methods
Cell culture and selection of resistant cells
CCRF-CEM cells (a human T-cell acute lymphoblastic leukemia
cellline [23])weremaintained assuspensionculturesinRPMI-1640
(Gibco, Invitrogen, Mount Waverly, Victoria, Australia) medium
containing 10% fetal calf serum (FCS; Gibco, Invitrogen). Resistant
diploid CCRF-CEM cells were selected by four sequential
treatments of 4 mM ZM447439 (Tocris, Bristol, UK) for 72 hr
until cells were able to proliferate through treatment. After each
treatmentthe population ofviablecellswasseparatedand recovered
from dead cells by a published procedure [24]. The resulting
resistant cell line designated CEM/AKB4 has since been main-
tained in drug free media. To generate sublines with higher levels of
resistance, CEM/AKB4 cells were selected for growth in 8 mM and
designated CEM/AKB8, and 16 mM ZM447439, designated
CEM/AKB16. All cells used in this study were mycoplasma free.
Growth inhibition assays
Growth inhibition assays were performed as previously
described [25]. Briefly, cells were seeded at 15,000 cells/well in
96-well plates in the presence or absence of the indicated drug
concentrations. Cytotoxic drugs were obtained as follows:
AZD1152, MLN8237 (Selleck Chemicals, San Diego, CA)
vincristine (Sigma); vinblastine (David Bull Laboratories, Lid-
combe, NSW, Australia); doxorubicin (Pharmacia, Rydalmere,
NSW, Australia); epothilone B and paclitaxel (Calbiochem, San
Diego, CA); ENMD2076 (Entremed, Ontario, Canada). After
72 hr incubation, metabolic activity was detected by addition of
Alamar blue and spectrophotometric analysis. Cell numbers were
determined and expressed as a percentage of control, untreated
cells. Determination of IC50 values and statistical analysis was
performed as described previously [26].
Cell cycle analysis by flow cytometry
Distribution of DNA content in CEM and CEM/AKB4 cells
was determined by flow cytometry as previously described [27].
Briefly, cells were harvested, washed with PBS, and then stained
for 15 min at 37uC with a solution containing 0.4% Triton X-100
(Sigma-Aldrich), 50 mg/mL of propidium iodide (Sigma-Aldrich),
and 2 mg/mL of DNase-free RNase (Roche). The cells were then
analyzed for cell cycle perturbation using a FACSCalibur (Becton
Dickinson) flow cytometer. The CellQuest program was used to
quantitate the distribution of cells in each cell cycle phase: sub-G1
(cell death), G1, S, and G2-M.
Real-time PCR analysis
Total RNA was extracted using RNeasy Mini kits (Qiagen)
according to the manufacturer’s instructions and was used to
prepare complementary DNA (cDNA) as previously described.
The cDNAs were used to quantify gene expression for AurkB and
MDR1 by real-time PCR using Taqman Gene Expression assays
(Applied Biosystems) containing 6-carboxyfluorescein (FAM)
labelled probes. PCR reactions were performed using the ABI
Prism 7500 sequence detection system (Applied Biosystems) with a
25 mL reaction mixture containing 2 mL of cDNA template,
12.5 mL TaqMan Gene Expression PCR Master Mix (Applied
Biosystems) and 1.25 mL Taqman assay. Cycling conditions were
as follows: 50uC for 2 min, 95uC for 10 min, 40 cycles of 95uC for
15 s and 60uC for 1 min. Gene expression was normalised to the
cyclophilin-A gene (PPIA) employed in multiplex using a TaqMan
Endogenous Control assay (Applied Biosystems).
Western blot analysis
Total cell lysates were separated by SDS-PAGE and electro-
transferred to nitrocellulose membrane using standard methods.
Primary antibodies used were rabbit monoclonal anti-Aurora
kinase B ([EP1009Y], Abcam), rabbit monoclonal anti-phospho
Histone H3(Ser10) ([D2C8], Cell Signaling), rabbit anti-cleaved
PARP (Asp214) (Cell Signaling) and mouse monoclonal anti-
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) ([6c5],
Abcam). Detection was performed using HRP-conjugated goat-
anti-rabbit (Pierce) and sheep anti-mouse (Amersham) secondary
antibodies. Bands were detected by the ECL Plus Western Blotting
Detection reagent (GE Healthcare) and visualised and imaged on
a Typhoon 9410 laser scanner (GE Healthcare). Relative
expression is given as the ratio of the test band’s densitometric
volume to that of the respective GAPDH band.
Immunofluorescence staining
Briefly, cells were plated in glass chamber slides and allowed to
reach 70% confluence. Immunofluorescence staining was then
done as described previously [28]. For dual staining, cells were first
stained with an Aurora B antibody (Abcam) followed by Alexa-488
anti-mouse fluorescent-tagged antibody (GE Healthcare). This was
then followed by staining with a-tubulin and Alexa-555 anti-
mouse fluorescent-tagged antibody (GE Healthcare). Slides were
mounted on a coverslip using DAPI II Counterstain (Vysis, Inc.).
Immunofluorescence microscopy was done using a Zeiss Axioplan
2 Microscope (Zeiss), and images were captured using a Sensicam
Charged Coupled Device camera (PCO Imaging) and the Image-
Pro Plus 4.1 software (Media Cybernetics, L.P.).
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The parental CCRF-CEM and CEM/AKB resistant cells were
either untreated or treated with 4 mM of Aurora B kinase inhibitor
(ZM447439) for 24 hours and 5610
4 cells were cytospun onto
glass slides. Mitotic index was determined as previously described
[29]. At least 1000 interphase and mitotic cells were counted per
condition from at least three independent experiments. Mitotic
index was calculated by dividing the total number of mitotic cells
by the total number of interphase and mitotic cells counted.
Sequencing of AurkB gene
Gene sequencing was performed on cDNA from CEM and
CEM/AKB4 cells as prepared above. Gene specific PCR primers
were used to amplify the full length of the AurkB (accession
no. NM_004217.2) coding region by using three overlapping
primer sets. Sequences of the overlapping primer sets are as follows.
AKB -13F 59TTTCTCTCTAAGGATGGCCC
AKB 328R 59TGAAGAGGACCTTGAGCGCC
AKB 243F 59TCCTCTGGGCAAAGGCAAG
AKB 638R 59TCTCCCTTGAGCCCTAAGAG
AKB 508F 59TGCACATTTGACGAGCAGCG
AKB 39UTR 41R 59AGACATACAAACACACGCACC
Amplification reactions had the following components: 16PCR
Gold Buffer (Applied Biosystems), 0.2 mM deoxynucleoside
triphosphates (dNTPs), 250 ng of each primer, 1.5 mM MgCl2
solution (Applied Biosystems) and 2 U AmpliTaq Gold Polymer-
ase (Applied Biosystems) in total volume of 50 ml. PCR cycle
conditions were: 94uC 5 min, 35 cycles of 94uC4 5s ,5 7 uC4 5s ,
72uC 45 s followed by 72uC for 7 min. Amplified PCR products
were resolved on a 1% agarose gel stained with crystal violet. The
desired band was excised, DNA purified by using the QIAquick
gel extraction kit (Qiagen) and sequenced with BigDye termina-
tors. Sequence analyses were performed at the Sydney University
Prince Alfred Molecular Analysis Centre (SUPAMAC).
Apoptosis assays
Cellular apoptosis was determined by measurement of cleaved
PARP (cPARP). Briefly, CEM, CEM/AKB4 and CEM/AKB16
cells were treated with varying concentrations of ZM447439 for
24 h.Followingtreatment,cells were harvested andlevelsofcPARP
determined by westernblotting.Additionally, inductionofapoptosis
was determined by measurement of Annexin V-FITC (Becton
Dickinson) using flow cytometry as described previously [27].
Molecular modelling and docking
Docking was performed with Glide 5.0 [30] from Schro ¨dingerH.
Initially the Aurora B (xenopus laevis) crystal structures co-
crystallised with ZM447439, hesperadin, and an aminothiazole
inhibitor (pdb codes: 2VRX, 2BFY and 2VGP respectively) were
individually imported into the Maestro 8.5 [31] graphical user
interface; protein preparation and refinement was employed on all
structures. The glycine 176 (G176) residues of Aurora B in the
above structures were mutated to glutamate (E176) to generate the
mutant structures and these structures were prepared and refined as
before. The Protein preparation module allows the refinement of
the protein crystal structure by deleting crystal water molecules,
adding hydrogens, restoring bond orders and correcting any steric
clashes among different amino acid residues. To use these structures
for ligand docking the shape and properties of the receptor should
be represented on a grid; the receptor grid generation module in
Glide 5.0 was used to generate four different grids for each of the
crystal structures and their corresponding mutants. The binding site
to be used for docking was determined as a centroid of the crystal
structure ligand position. The Coulomb-van der Waals (vdW) radii
of the receptor residues were set as 1.
The docking process followed by flexibly docking each ligand
into the corresponding wild-type and mutant protein structures,
the extra precision (XP) function was used in all the docking runs
and the vdW scaling of 1.0 was used for the ligands vdW radii.
Ligands were built using the Maestro 8.5 [31] graphical user
interface and were minimized with the MacroModel 9.6 [32]
module using the OPLS_2005 force field [33].
Statistical analysis
Statistical analysis was performed using the GraphPad Prism
program. Results were expressed as means of at least three
independent experiments 6 SEM. A two-tailed Student’s t test was
used to determine the statistical differences between various
experimental and control groups, with P,0.05 considered
statistically significant.
Results
Selection of ZM447439 resistant leukaemia cells
Prior to developing Aurora B inhibitor resistant leukaemia cells
cytotoxicity assays on CCRF-CEM T-cell leukemia cells were
performed using ZM447439 (ZM). The IC90 for ZM against
CCRF-CEM cells was 4 mM. Selection of a ZM-resistant CEM
subline was achieved by sequential 72 hr treatments of CEM cells
with 4 mM ZM followed by recovery and expansion of the
surviving population. Resistance was defined as cells being able to
proliferate in the presence of the IC90 drug concentration. Four
72 hr treatments of CEM cells with 4 mM ZM yielded a resistant
population designated CEM/AKB4. To determine the levels of
resistance of CEM/AKB4 cells to ZM, cytotoxicity assays were
performed. The activity of the drug was approximately an order of
magnitude lower in CEM/AKB4 cells relative to CEM cells
(Fig. 1). The relative resistance of CEM/AKB4 was 13.2 fold when
compared to parental CEM cells (Table 1).
CEM/AKB4 cells are not cross-resistant to other classes of
cytotoxic agents
To determine whether CEM/AKB4 cells are cross resistant to
similar and differing classes of cytotoxic agents, cytotoxicity assays
using a selective Aurora B inhibitor (AZD1152), a selective Aurora
kinase A inhibitor (MLN8237), mitotic inhibitors that target tubulin
(vincristine, vinblastine, paclitaxel and epothilone B), a DNA
damaging agent (doxorubicin) and a multi-kinase inhibitor
(ENMD2076) against CEM/AKB4 cells were compared to those
for the parental CEM cell line (Table 1). CEM/AKB4 cells were 7
fold cross resistant to AZD1152 but were not resistant to any of the
otherdrugclasses.TheCEM/AKB4cellswere hypersensitive tothe
Aurora A inhibitor MLN8237. A trend towards hypersensitivity for
vincristine, paclitaxel, doxorubicin and ENMD2076 was observed
but the relative resistance values were not statistically significant.
Resistance is not due to up-regulation of multi-drug
resistance proteins in CEM/AKB4 cells
ZM is thought to be a substrate of the multi-drug resistance
protein P-glycoprotein and we sought to determine whether up-
regulation of P-glycoprotein may mediate resistance to ZM in
CEM/AKB4. Cytotoxicity assays were conducted using ZM in the
presence or absence of the P-glycoprotein inhibitor verapamil.
The relative resistance of CEM/AKB4 cells to ZM treated with
verapamil was not significantly different to cells treated with ZM
alone, showing that verapamil was not able to restore sensitivity of
Mechanisms of Resistance to Aurora B Inhibitors
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glycoprotein is not a likely resistance pathway in these cells
(Figure 1). We also excluded the role of multi-drug resistance
ABCC gene family members in the resistance phenotype as there
was no significant change in the expression of MDR1 or of
ABCC1, 3, 4, 7, 10, or 11 in the CEM/AKB4 cells (Figure S1).
Cell cycle analysis
Aurora B inhibitors such as ZM exert their cytotoxic effects by
disrupting processes crucial for cell cycle progression. We examined
the ability of ZM to induce cell cycle changes in the resistant cells
using flow cytometry. Cell cycle analysis was performed on CEM or
CEM/AKB4 cells treated for 24 hr in the presence or absence of
0.4, 0.75 and 4.0 mM ZM respectively (Figure 2). Without drug
treatment, the cell cycle profile of CEM/AKB4 cells appeared
similar to that of CEM with no observed change in proportion of
cells in each phase of the cycle. Upon treatment with a low dose of
ZM the profile of CEM cells showed disruption to the cell cycle
consistent with inhibition of Aurora B: an increase in DNA content
due to cytokinesis failure and increased sub G1 population
indicative of cell death [13]. These characteristics became more
pronounced with increasing drug concentration. However no
changes in the profile of CEM/AKB4 cells were observed upon
drug treatment even at higher concentrations (eg 4 mM) that cause
massive cell death in the parental CEM cell line. Clearly the
inability of ZM to exert its cell cycle disrupting effects is a pathway
contributing to the resistance of the CEM/AKB4 cells.
Aurora B is down-regulated in CEM/AKB4 cells but
catalytically active
To determine whether changes in Aurora B gene and/or protein
expression were associated with resistance in CEM/AKB4 cells we
performed real-time PCR and western blotting. Real-time PCR
analysis of cDNAs from CEM and CEM/AKB4 cells showed that
gene expression of Aurora B was modestly but significantly lower in
the resistant cell line (Figure 3A). Similarly, protein expression as
determined by western blotting was almost 50% lower in CEM/
AKB4 compared to the parental CEM cells (Figure 3B). We then
asked whether catalytic activity of Aurora B is maintained in CEM/
AKB4 cells in the presence of ZM447439. CEM and CEM/AKB4
cells were treated for 24 hr with increasing concentrations of
ZM447439 and the levels of phosphorylated Histone H3(Ser10)
determined by western blotting (Figure 3C). ZM447439 clearly
suppressed H3(Ser10) phosphorylation in the parental CEM cells,
however, levels of phosphorylated H3(Ser10) were relatively
unchanged in CEM/AKB4 cells when treated with up to 4 mM
ZM447439. Additionally we performed similar gene and protein
expression analyses for Aurora A to determine whether resistance
may be mediated through an Aurora A dependent pathway. No
differencesin either gene or protein expression of AuroraA in CEM
and CEM/AKB4 cells were observed (data not shown).
To address whether the localization of Aurora B was altered in
the resistant CEM cells, immunofluorescence staining was
employed. As expected, in CEM cells Aurora B is maximally
expressed in mitotic cells and localises to centromeres in
metaphase, to the spindle midzone in anaphase/telophase and
to the midbody in cytokinesis (Figure S2). In several independent
experiments no difference in Aurora B localization was observed
between CEM and CEM/AKB4 cells. The mitotic indices for
both CEM and CEM/AKB4 cells were obtained in the presence
Figure 1. Resistance levels of CEM/AKB4. (A) Plot of cell viability against concentration of ZM447439 for both CEM/AKB4 and parental CEM cells
as determined by cytotoxicity assay. (B) Results of the same experiment performed in the presence of the P-glycoprotein inhibitor verapamil. Points
are the means, and bars are the SEM of at least three independent experiments.
doi:10.1371/journal.pone.0030734.g001
Table 1. Relative resistance of CEM/AKB4 cells to cytotoxic
agents compared to parental CCRF-CEM cells.
Drug Cell line IC50
Relative
Resistance
a P
ZM447439 CEM 3.4060.37610
27 -
CEM/AKB4 4.5560.29610
26 13.4 ,0.0001
AZD1152 CEM 3.4960.36610
28 -
AKB4 2.4760.27610
27 7.08 0.0015
ENMD2076 CEM 2.6760.46610
27 -
CEM/AKB4 1.3760.42610
27 0.513 0.1055
MLN8237 CEM 8.8460.46610
28 -
CEM/AKB4 5.7460.27610
28 0.65 0.003
Vincristine CEM 2.0760.29610
29 -
CEM/AKB4 1.0860.28610
29 0.522 0.0686
Vinblastine CEM 3.1360.07610
29 -
CEM/AKB4 3.2360.03610
29 1.03 0.2508
Paclitaxel CEM 2.1860.69610
28 -
CEM/AKB4 8.865.6610
29 0.404 0.2184
Epothilone B CEM 2.2760.12610
29 -
CEM/AKB4 2.7360.26610
29 1.20 0.1790
Doxorubicin CEM 5.3961.54610
28 -
CEM/AKB4 3.0360.37610
28 0.562 0.2120
aDetermined by dividing the IC50 for the resistant (CEM/AKB4) cell line by the
IC50 of the parent (CEM) cell line.
doi:10.1371/journal.pone.0030734.t001
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were observed either in basal levels or drug treated levels (Table 2).
Collectively, these results suggest that despite decreased expression
levels, localization and catalytic function of Aurora B is not
impaired in resistant CEM/AKB4 cells compared to CEM.
CEM/AKB4 cells express a point mutation in Aurora B
Point mutations in the catalytic domain are known to confer
resistance of cancer cells to kinase inhibitors so we sought to
determine whether kinase domain or other mutations are contrib-
uting to the resistant phenotype in CEM/AKB4 cells. Accordingly
the full length sequence of the Aurora B gene was obtained and
compared between CEM and CEM/AKB4 cells. As ZM447439 is
known to inhibit Aurora A the full length sequence of this gene was
also determined. The resistant CEM/AKB4 cells featured a single
point mutation in the kinase domain of Aurora B that gives rise to a
G160E amino acid substitution (Figure S2). This residue lies in the
hinge region of the catalytic domain of the protein, an important site
involved in Aurora B inhibitor binding [34]. In contrast, no
mutations were detected in the Aurora A gene were detected.
G160E substitution impairs Aurora B inhibitor binding
Interestingly the G160E substitution has also been described in
ZM resistant colorectal cancer cells suggesting that this is an
important residue in ZM binding [21]. The mutation has been
presumed to mediate resistance by hindrance of drug binding
through steric interactions with the bulkier glutamate residue. To
further elucidate the role of the G160E mutation we used a
molecular modelling approach with docking studies to explore the
influence of this substitution on Aurora B inhibitor binding and
resistance mechanisms. In our methodology the initial templates
were based upon available crystal structures of inhibitors bound to
xenopus laevis Aurora B from whence we employed docking
calculations with the corresponding inhibitor as described in the
Materials and Methods section. The three inhibitors and their
corresponding crystal structure PDB entries were ZM447439
(2VRX), hesperadin (2BFY) and an aminothiazole inhibitor
(2VGP) with the starting templates prepared by removing the drug
molecule from the crystal structure and substituting glycine at the
160 position (176 in xenopus laevis Aurora B) for glutamate for the
case of the mutant docking calculations. Each drug was then docked
into the ATP binding pocket with calculations yielding several
docked poses. Examination of the docked poses in wild type Aurora
B showed that the drug molecules adopted similar conformations
and binding modes to those observed in the corresponding crystal
structures, validating the models and our methodology (Figure S3).
These calculations showed that ZM and hesperadin formed
hydrogen bonds to the Ala173 (2.602 A ˚ for ZM, 2.897 A ˚ for
hesperadin) and Lys122 (1.889 A ˚ for ZM, 2.873 A ˚ for hesperadin)
residues of Aurora B that have been previously demonstrated to be
key interactions for potent Aurora B inhibition [35,36]. The
aminothiazole inhibitor on the other hand formed hydrogen bonds
to Ala173 (2.00 A ˚) and Leu99 (2.974 A ˚) but not Lys122 and this
alternative binding motif has been postulated to be responsible for a
different mode of action for this drug. ATP was also docked into the
binding cavity and likewise assumed similar poses to confirmations
observed in crystal structure determinations (Figure S4A). We then
repeated the same docking calculations in the mutant Aurora B
templates. Initially ATP was docked into the mutant enzyme and
importantly showed similar binding patterns and orientations as
observed in the wild-type enzyme (Figure S4B), suggesting that
catalytic activity of Aurora B is maintained in the presence of the
mutation. Docking of the ZM and hesperadin molecules into the
mutant Aurora B containing the bulkier Gln176 residue produced
poses significantly different to those in the wild type enzyme
(Figure 4). These inhibitors did not penetrate as deep into the
binding pocket as for the wild type enzyme even though this cavity
in the mutant is still relatively large. In particular the ZM molecule
resides largely outside this region. Moreover both molecules
adopted different orientations in the binding site of the mutant
compared to wild-type enzymes introducing alternative chemical
moieties into this region. The active binding motif present in
docking in the wild type Aurora B was missing, with hydrogen
bonds to Lys122 absent for both molecules. According to our
criteria, therefore, none of the docked poses corresponded to a
conformation that would significantly inhibit kinase activity of
Figure 2. Cell cycle analysis of CEM and CEM/AKB4 cell lines. After ZM treatment (24 h), cells were harvested and assayed for their DNA
content by flow cytometry. Figures are representative of three independent experiments.
doi:10.1371/journal.pone.0030734.g002
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aminothiazole inhibitor in the mutant Aurora B were nearly
identical to those observed in the wild type with the same
orientation and hydrogen bonding patterns present.
Increased ZM447439 selective pressure leads to
increased gene expression of MDR1
A key question was whether increasing drug selective pressure on
the CEM/AKB4 cells would lead to more highly resistant cells with
additional resistance mechanisms. To address this we examined
resistance mechanisms in cells more highly resistant to ZM447439,
with the CEM/AKB8 and CEM/AKB16 sublines generated by
sequential treatments of CEM/AKB4 cells with 8 mMa n d1 6mM
ZM447439 respectively. The CEM/AKB8 and CEM/AKB16
sublineswere 14.8- and 155-foldresistanttoZM447439 respectively
compared to parental CEM cells as determined by cytotoxicity
assays. Proliferation of the cells compared to CEM cells was
determined in the presence and absence of 4 mM ZM447439 and
showed that basal levels of proliferation across all cells were not
appreciably different (Figure 5). As observed for CEM/AKB4 cells,
CEM/AKB8 and CEM/AKB16 cells continued to proliferate in
the presence of the selecting agent (Figure 5). Gene and protein
expression of Aurora B was analysed to establish whether any
Figure 3. Gene and protein expression of Aurora B in CEM and CEM/AKB4 cells. (A) AurkB gene expression as determined by real-time PCR.
Expression is displayed as relative DDCt values of CEM/AKB4 compared to that for CEM with Ct values normalised to the cyclophilin-A gene (PPIA). (B)
Aurora B protein expression determined by western blot. The densitometric volume of the Aurora B band is expressed relative to the densitometric
volume of the loading control gene GAPDH. Error bars represent the SEM of three independent experiments. * p,0.05, ** p,0.005. (C) Detection of
phospho Histone H3(Ser10) in CEM and CEM/AKB4 cells treated for 24 hr with increasing concentrations of ZM447439 by western blotting. Shown are
representative blots from three independent experiments.
doi:10.1371/journal.pone.0030734.g003
Table 2. Mitotic index of CEM and CEM/AKB4 cells in the
presence and absence of 4 mM ZM447439.
Mitotic index (%)*
Cell line Untreated 4 mM ZM447439
CEM 7.8060.56 8.8960.46
CEM/AKB4 8.2760.28 8.3260.61
*Percentages of mitotic cells were calculated after counting at least 1000 cells in
three independent experiments.
doi:10.1371/journal.pone.0030734.t002
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AKB8 and CEM/AKB16 cells. Interestingly, while both gene and
protein expression of Aurora B in CEM/AKB4 cells were lower
than CEM cells, expression levels reverted to near equivalence with
increasing selective pressure (Figure S5). Full length sequencing of
the Aurora B gene in CEM/AKB8 and CEM/AKB16 cells showed
the G160E substitution present in CEM/AKB4 cells was preserved,
however no additional point mutations were found. Gene and
protein expressionofAuroraA wasanalysedbutnodifferenceswere
identified between CEM cells and CEM/AKB8 and CEM/AKB16
cells (data not shown). Moreover, no mutations in Aurora A were
detected.Toestablishwhetherup-regulationofmultidrugresistance
proteins was associated with a higher level of resistance to
ZM447439, the expression of MDR1 and ABCC1, 2, 3 and 4
genes in CEM/AKB8 and CEM/AKB16 cells was determined by
real-time PCR. Whilst expression of MDR1 mRNA was not
appreciably altered in CEM/AKB4 cells compared to CEM, levels
increased ina dose dependant mannerforCEM/AKB8and CEM/
AKB16 cells, with approximately 2- and 5-fold increases respec-
tively (Figure 6A). However the increased MDR1 expression was
not functionally relevant as sensitivity to doxorubicin, a P-
glycoprotein substrate, was not altered in CEM/AKB16 cells
compared to CEM cells using cytotoxicity assays (Figure 6B).
Uptake of Daunorubicin, another P-glycoprotein substrate, was not
reduced in these same cells as determined by flow cytometry (data
not shown). Expression of ABCC1, 2, 3 and 4 was unaltered in all
CEM/AKB cells compared to CEM cells (data not shown).
CEM/AKB16 cells are resistant to apoptosis and Aurora B
inhibition
Given that the CEM/AKB16 cells are highly resistant to
ZM447439 and this is not due to additional mutations in Aurora
kinase B, or reduced drug transport, we focused on the ability of
the CEM/AKB16 cells to undergo apoptosis in the presence of
drug. CEM/AKB16 and CEM cells were treated with increasing
concentrations of drug and monitored for the expression of
markers of apoptosis after 24 hr (Figure 7). Apoptosis indicated by
cleavage of PARP, a substrate of the apoptotic caspases, is strongly
induced in CEM cells by treatment with 4 and 8 mM ZM447439,
however the level of this induction is far less in CEM/AKB4 and
CEM/AKB16 cells (Figure 7A). Furthermore, upon treatment
with 16 mM ZM447439 for 24 hr the proportion of apoptotic cells
as determined by Annexin V-FITC staining is increased for CEM
and CEM/AKB4 cells compared to control untreated cells, yet
remains unchanged in CEM/AKB16 cells (Figure 7B). Together
these results suggest that resistance to apoptosis is a primary
mechanism mediating the phenotype of CEM/AKB4 and also the
more highly resistant CEM/AKB16 cells.
To determine whether the high level resistance of CEM/
AKB16 to ZM447439 is mediated by inhibition of Aurora B, or
Figure 4. Docking of Aurora B inhibitors with the catalytic domain of wild-type and mutant Aurora B with the G160E substitution
(G176E for xenopus laevis). Docked poses were compared between wild-type and mutant Aurora B for (A, B) ZM447439, (C, D) hesperadin and (E,
F) aminothiazole inhibitor. Hydrogen bonds referred to in the text highlighted in yellow.
doi:10.1371/journal.pone.0030734.g004
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in cells treated with 16 mM ZM were analysed by western blotting
(Figure 8). As expected, CEM cells treated with 16 mM ZM have
dramatically lower levels of phospho H3 compared to untreated
cells consistent with inhibition of Aurora B. However phospho H3
levels in both treated and untreated CEM/AKB4 and CEM/
AKB16 cells are not appreciably different. This data strongly
suggests that Aurora B remains catalytically active in the presence
of high drug concentrations and this may be mediating the highly
resistant phenotype in the CEM/AKB16 cells.
Discussion
Understanding the molecular factors that contribute to sensitivity
and resistance to new chemotherapeutic agents is crucial to their
effective implementation in treatment regimes. Moreover, establish-
ing the drug-target interactions mediating these processes allows for
the rational design of more potent and effective molecules. Herein
we have described the development and characterisation of Aurora
B inhibitor resistant leukemia cell lines that have acquired multiple
genetic defects including i) a point mutation in the Aurora B kinase
domain and ii) decreased ability to undergo apoptosis. Hematolog-
ical malignancies have proven to be particularly responsive to these
agents in early clinical evaluation and hence our findings could be
important to optimise future efficacy against leukemia.
Characterisation of CEM/AKB4 cells revealed that resistance is
not mediated by multidrug resistance pathways. CEM/AKB4 cells
were not cross-resistant to a broad range of cytotoxic agents,
including an Aurora A inhibitor, and moreover, did not show
transcriptional activation of ABCC family drug transporters. The
CEM/AKB4 cells were hypersensitive to the Aurora A inhibitor
MLN8237. CEM/AKB4 cells were, however, cross resistant to a
selective Aurora B inhibitor, AZD1152, indicating an Aurora B
dependant mechanism of resistance. Although ZM447439 is known
to inhibit Aurora A we excluded the possibility of an Aurora A
dependent mechanism contributing to resistance to these cells by
the lack of Aurora A gene and protein alterations in CEM/AKB4
cells and a lack of cross resistance to the selective Aurora A inhibitor
MLN8237. This is in agreement with other reports that show the
cytotoxic activity of ZM447439 is mediated through Aurora B, not
Aurora A inhibition [16]. Detection of a G160E point mutation in
the kinase domain of Aurora B suggested that resistance in CEM/
AKB4 cells is mediated through impaired binding of the drug to the
target kinase. Genetic alterations to drug targets are common
mechanisms mediating resistance to targeted therapies; point
mutations in BCR-ABL conferring resistance to Imatinib in
leukaemia is a classic example. Moreover, the G160E mutation in
Aurora B has been reported in colorectal cells selected for resistance
to ZM447439. Our findings in a leukaemia cell line further validate
that the 160 position is particularly important for drug binding and
that point mutations of this residue afford highly penetrant
resistance. This mutation should be validated in a clinical setting
as it may be important in the use of Aurora B inhibitors and
resistance to therapy, much as the T315I BCR-ABL mutation is
highly prognostic of outcome for Imatinib treatment in CML
patients. As yet, the G160E mutation has not been reported in
studies of Aurora B inhibitors in animal models or clinical studies.
Although the Aurora B G160E substitution has been shown to
independently confer resistance to Aurora B inhibitors it has not
been conclusively shown how drug binding is affected. We
therefore employed a molecular modelling approach to under-
stand how the G160E substitution alters drug binding and to gain
further insights into drug-target interactions of Aurora B
inhibitors. Our docking results confirm that binding of ATP to
Figure 5. Proliferation timecourse of CEM and CEM/AKB cells in
the presence and absence of ZM447439. Cells were grown either
in vehicle alone or in 4 mM ZM447439 and proliferation was determined
at indicated timepoints as the corrected absorbance using the Alamar
blue assay measured spectrophotometrically. Error bars represent the
SEM of three independent experiments.
doi:10.1371/journal.pone.0030734.g005
Figure 6. Expression and functional relevance of MDR1 (P-glycoprotein) in CEM/AKB cells. A) CEM/AKBMDR1 mRNA expression in
ZM447439 resistant CEM cells as determined by real-time PCR. Expression is displayed as relative DDCt values of CEM, CEM/AKB4, CEM/AKB4 and
CEM/AKB4 cells compared to that for CEM/VCRR cells with Ct values normalised to the cyclophilin-A gene (PPIA). Error bars represent the SEM of
three independent experiments. B) Cytotoxicity assays of doxorubicin against CEM and CEM/AKB4, 8, and 16 cells.
doi:10.1371/journal.pone.0030734.g006
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type, thereby maintaining catalytic activity. We showed that
hydrogen bonding of Aurora B inhibitors to the Ala173 and
Lys122 residues are key interactions mediating drug activity by
preventing catalytic binding of ATP. However, the presence of the
G160E mutant hinders the ability of inhibitors to penetrate as far
into the binding pocket as the wild-type enzyme precluding the
formation of these hydrogen bonds. Presumably inhibitors are only
able to bind to the mutant enzyme in modes that do not compete
effectively with ATP and substrate binding, thereby allowing
catalytic activity in the presence of the drug and a resistant
phenotype. It would be expected that any Aurora B inhibitor that
has a similar active binding motif would be affected, explaining the
cross resistance of cells with this mutation to structurally related
inhibitors in our studies and others [21]. Our models could
therefore be used as a screen to identify, or rationally design,
inhibitors with novel binding modes that may abrogate Aurora B
G160E mediated resistance.
The progression of resistance with repeated or higher concentra-
tion drug exposure is an important consideration in the treatment of
relapsed disease.BothCEM/AKB8 andCEM/AKB16cellsshowed
a dose dependent increase in transcriptional activity of MDR1,
however P-glycoprotein was not functionally active in either case.
Moreover, both parental CEM cells and resistant CEM/AKB8 and
CEM/AKB16 cells were equally sensitive to doxorubicin suggesting
an absence of a multidrug resistance phenotype. Nevertheless,
CEM/AKB16 cells showed an increased resistance to apoptosis as
measured by levels of c-PARP and Annexin V. Resistance to kinase
inhibitors may also be effected by aberrant activation of redundant
signalling pathways to that of the target, an example being MET
amplificationinresistancetoEGFRkinaseinhibitors[37].AsCEM/
AKB16 cells were highly resistant to Aurora B inhibition it appears
that sustained Aurora B activity in the presence of ZM447439 may
still be driving resistance in these cells rather than activation of an
alternative pathway. Previous work from our laboratory on drug
resistance mediated by tubulin mutations showed that CEM cells
acquire additional point mutations in tubulin at higher levels of
resistance [26]. Both CEM/AKB8 and CEM/AKB16 cells
expressed the Aurora B G160E mutation described for CEM/
AKB4 cells, however no additional mutations in Aurora B were
observed,furtherdemonstratingtheimportanceofthe160residuein
drug binding and high-level resistance.
Our study of phosphorylated Histone H3 levels showed that
CEM/AKB4 cells maintain resistance to Aurora B inhibition at
16 mM ZM, despite this drug concentration being sufficient to
Figure 7. Induction of apoptosis in CEM and CEM/AKB cells. A) Levels of cleaved PARP in cells treated with indicated concentrations of
ZM447439 for 24 h as determined by western blot. B) Proportion of apoptotic cells in both untreated and CEM and CEM/AKB cells treated with 16 mM
ZM447439 for 24 h.
doi:10.1371/journal.pone.0030734.g007
Figure 8. Levels of phosphorylated Histone H3 in CEM and
CEM/AKB cells in the presence or absence of 16 mM ZM447439.
doi:10.1371/journal.pone.0030734.g008
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kinase inhibition of ZM447439, where at high drug concentrations
the contribution of targeting additional cytotoxic pathways to
Aurora B inhibition becomes significant. Therefore the resistant
phenotype in CEM/AKB16 cells may potentially be mediated
through alterations in these other targets of ZM447439. ZM447439
has been shown to potently inhibit Aurora A as well as Aurora B in
biochemical assays [18] and we analysed CEM/AKB16 cells for
alterations in Aurora A. We found no changes in gene or protein
expression of Aurora A in CEM/AKB16 cells and no mutations in
the Aurora A gene (data not shown). Additionally, CEM/AKB16
cells were as equally sensitive as CEM cells to a selective Aurora A
inhibitor MLN8237 (data not shown), suggesting that ZM447439
resistance in these cells is not mediated through an Aurora A
dependent pathway. It is possible that alterations in other unknown
targets of ZM447439 may be responsible, and ultimately, an
understanding of the precise mechanisms underpinning resistance
in the more highly resistant CEM/AKB8 and CEM/AKB16 cells
will shed further light on the mode of action of this drug.
Aurora B inhibitors remain a promising area for targeted
anticancer therapy, yet a fuller understanding of drug response
and resistance mechanisms will aid their clinical implementation.
Our findings have confirmed that resistance to these agents is likely
across a variety of malignancies and that point mutations in Aurora
B, particularly of the 160 residue, may be highly significant markers
of treatment outcome. Moreover, our analysis of highly resistant
cells suggests that sustained or high-level drug treatment may give
rise to an evolution of multiple mechanisms of resistance in patients.
Accordingly, our models provide a basis for designing and testing
alternative Aurora B inhibitors, and for screening agents that may
be employed in combination therapeutic approaches.
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Figure S1 Relative gene expression of common ABCC
drug transporter proteins in CEM/AKB4 cells compared
to parental CEM cells. Expression was determined by real-
time PCR using Taqman probes for MDR1 and ABCC1-12. Ct
values were normalised to PPIA and expression calculated by the
DDCt method. No expression was observed for ABCC3, 5, 6, 8, 9,
12 in either CEM or CEM/AKB4.
(PDF)
Figure S2 Localisation of Aurora B in mitotic CCRF-
CEM cells compared with CEM/AKB4 cells by immu-
nofluorescence staining. Cells were stained for Aurora B, a-
tubulin, and DNA (DAPI). Scale bar=10 mM.
(PDF)
Figure S3 Comparison between crystal structure of
Aurora B inhibitors cocrystallised with Aurora B and
docking of corresponding inhibitor with Aurora B used
to validate the methodology.
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Figure S4 Docking of ATP with the catalytic domain of
wild-type and mutant Aurora B with the G160E substi-
tution (G176E for xenopus laevis). Docked poses were
compared between (A) wild-type and (B) mutant Aurora B.
(PDF)
Figure S5 Gene and protein expression of Aurora B in
CEM and CEM/AKB cells. (A) AurkB gene expression as
determined by real-time PCR. Expression is displayed as relative
DDCt values of CEM/AKB4, AKB8 and AKB16 cells compared
to that for CEM with Ct values normalised to the cyclophilin-A
gene (PPIA). (B) Aurora B protein expression determined by
western blot. The densitometric volume of the Aurora B band is
expressed relative to the densitometric volume of the loading
control gene GAPDH. Error bars represent the SEM of three
independent experiments.
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